Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human TrialsMindMed Reports Full Year 2022 Financial Results and Business HighlightsCybin to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceNuminus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023Irwin Naturals Signs Letter of Intent to Acquire Braxia ScientificNuminus Wellness Inc. Reports Q1 2023 ResultsIrwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical CompanNuminus Develops Mushroom Tea for Use in Psychedelic ResearchIs the Psychedelic Sector Poised for a Comeback?!?PSYC + Nucleus Form New Partnership to Develop and Launch Psychedelic FinderWhat You Need to Know About Numinus Wellness…Numinus provides update on acquisition integration and announces new client financing optionsPSYC Corp’s Psychedelic Spotlight Surpasses One Million Page Views for Fourth Consecutive MonthNuminus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022The Psychedelic Sector is Quietly Outperforming the S&P 500PSYC Completes and Publishes 2021 Audited Financials; Will Begin Audit of Q1 & Q2 2022Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022PSYC’s Bonfire Platform Development Progresses; Will Host Free Virtual Community Event on August 29th

Insys Therapeutics: Sell, Sell, Sell

Jun 10, 2016 • 12:52 PM EDT
1 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

The U.S. Attorney’s Office for the Southern District of New York announced that Jonathan Roper, a former District Manager at Insys Therapeutics (INSY), and Fernando Serrano, a former sales representative at Insys, were charged with violating the Anti-Kickback Statute.

The charges were in connection with their participation in a “scheme to pay doctors thousands of dollars to participate in sham educational programs in order to induce the doctors to prescribe millions of dollars’ worth”

LinkedIn Provides the Missing Link

Although Insys Therapeutics was not named in the case, Serrano identifies himself as a former employee of Insys Therapeutics.

Additionally, the U.S. Attorney’s Office press release states that “Pharma Company-1’s fentanyl spray was approved by the FDA in or about January 2012.”

A Concerning Track Record

In June 2015, Heather Alfonso pled guilty in United States District Court in Hartford to having received $83,000 in kickbacks from Insys Therapeutics (INSY) during January 2013 through March 2015. Alfonso said the money influenced her prescribing a particular drug, according to the United States Attorney’s Office in Hartford, Connecticut.

Although Insys and the drug were not named in the indictment, in court a prosecutor revealed that the case involved Subsys and Insys Therapeutics.

Expect Weakness Ahead

During the last two years, several physicians who received speaking fees from Insys were disciplined or arrested for improperly prescribing Subsys. Last year, Dr. Gavin Awerbuch was arrested after federal prosecutors said he defrauded Medicare of $7 million and improperly prescribed Subsys to patients. Dr. Awerbuch was paid speaker’s fees by Insys, Another Insys speaker, Dr. Jerrold Rosenberg, was reprimanded last September for inappropriately prescribing Subsys and other painkillers.

Insys Therapeutics’ fentanyl spray is the only FDA-approved product that it currently has on the market. We expect significant weakness in shares of INSY and view the company as a short target. 

Share Share - Facebook Share - Twitter


Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.


Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.